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Abstract
Introduction: Glioma stem cells (GSCs) have the property of self-renewal and appear to be a driving force for the
initiation and recurrence of gliomas. We recently found that the human tumorigenic LN-229 glioma cell line failed
to form neurospheres in serum-free conditions and generated mostly small tumors in vivo, suggesting that either
LN-229 GSCs are not active in these conditions or GSCs are absent in the LN-229 cell line.
Methods: Using self-renewal assay, soft-agar colony assay, cell proliferation assay, invasion assay, real time PCR
analysis, ELISA and in vivo tumorigenic assay, we investigated the effects of interleukin (IL)-1b and transforming
growth factor (TGF)-b on the development of GSCs from LN-229 cells.
Results: Here, we demonstrate that the combination of IL-1b and TGF-b can induce LN-229 cells to form
neurospheres in serum-free medium. IL-1b/TGF-b-induced neurospheres display up-regulated expression of
stemness factor genes (nestin, Bmi-1, Notch-2 and LIF), and increased invasiveness, drug resistance and tumor
growth in vivo: hallmarks of GSCs. These results indicate that IL-1b and TGF-b cooperate to induce a GSC
phenotype in the LN-229 cell line. Induction of nestin, LIF and Notch-2 by IL-1b/TGF-b can be reverted after
cytokine withdrawal. Remarkably, however, up-regulated Bmi-1 levels remained unchanged after cytokine
withdrawal; and the cytokine-withdrawn cells maintained strong clonogenicity, suggesting that Bmi-1 may play a
crucial role in tumorigenesis.
Conclusions: Our finding indicates that glioma cells without self-renewal capability in standard conditions could
also contribute to glioma malignancy when cytokines, such as IL-1b and TGF-b, are present in the tumor
environment. Targeting GSC-promoting cytokines that are highly expressed in glioblastomas may contribute to the
development of more effective glioma therapies.
Introduction
Gliomas are the most common primary brain tumors in
adults and glioblastomas are the most malignant gliomas
(WHO grade IV). Despite substantial progress in early
diagnosis, surgery and radiation protocols, only 15% of
patients who undergo radical surgery are still alive
within two years after diagnosis [1]. The poor prognosis
is mainly attributed to the highly diffusive growth pat-
tern of glioblastoma cells into surrounding brain tissue,
preventing complete surgical removal. Although there
has been intensive effort devoted to understanding the
molecular mechanisms involved in the genesis and pro-
gression of glioma, effective treatment of this tumor
type still remains elusive [2,3].
Cancer stem cells (CSCs) or tumor-initiating cells
(TICs) are a subpopulation of tumor cells with the abil-
ity to undergo self-renewal and recapitulate the entire
tumor population [4]. Similar to CSCs from other types
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fied from human glioma tissues and glioma cell lines by
applying conditions typically used for isolation of neural
stem cells (NSCs) [5-9]. GSCs are characterized by the
ability of self-renewal to generate spheres termed “neu-
rospheres” or “glioma neurospheres” when cultured in
serum-free conditions supplemented with epidermal
growth factor (EGF) and basic fibroblast growth factor
(bFGF). These glioma neurospheres reflect biological
and pathological characteristics of primary gliomas, dis-
play resistance to chemo- and radiotherapies, and, more
importantly, have enhanced oncogenic potential, gener-
ating tumors that reproduce the characteristics of the
original tumors after intracranial transplantation
[8,10,11]. Thus, understanding the biology of GSCs may
provide therapeutic strategies for the better treatment of
glioma by targeting GSCs.
Self-renewal of GSCs appears to be a driving force for
“successful” tumor growth, and significant effort has
been made to elucidate its regulatory mechanisms [12].
In recent years, the in vitro neurosphere formation assay
in serum-free conditions has been established as a mea-
sure of GSC self-renewal [13]. This assay has been vali-
dated by use of xenotransplantation models that are
considered as the gold standard for evaluation of GSC
self-renewal and tumor initiation [6]. Accordingly, the
ability to form neurospheres in vitro is defined as an
important aspect of GSCs [14], and has been employed
to verify GSCs that are isolated from gliomas using var-
ied methods, as well as to determine molecular factors
that regulate self-renewal of GSCs [15,16].
Inflammatory cytokines play a key role in malignant
progression of various cancer types [17]. In human glio-
blastomas, pro-inflammatory cytokines, interleukin (IL)-
1, IL-6 and IL-8, are expressed and secreted at high
levels, and their expression levels are correlated with the
histological grade of the neoplasms [18-21]. The essen-
tial role of IL-6 in glioma development has been demon-
strated in a mouse model [22]. Transforming growth
factor-b (TGF-b), an immunosuppressive cytokine, is
also significantly elevated in high-grade gliomas and
increased TGF-b activity confers poor prognosis in
glioma patients [23,24]. It has been suggested that the
inflammatory cytokines contribute to tumor malignancy
by promoting invasion, metastasis, angiogenesis and eva-
sion from immune attack [17,25,26]. Interestingly, these
cellular behaviors promoted by cytokines are also char-
acteristics of GSCs [27], suggesting that cytokines may
contribute to the development of GSCs. Indeed, recent
findings suggest that cytokine signaling pathways play a
critical role in the regulation of GSC self-renewal. For
example, higher expression levels of IL-6 receptors have
been found in GSCs than non-stem glioma cells, and
targeting IL-6 ligand or receptor expression in GSCs
significantly reduced neurosphere formation and tumor
growth [16]. TGF-b signaling has also been shown to
increase self-renewal capacity and prevent differentiation
of GSCs [28-31].
However, these studies focus on a rare population of
GSCs that can actively divide in serum-free medium to
elucidate self-renewal regulatory mechanisms. Recent
data show that not all GSCs can generate neurospheres,
suggesting that there are different subtypes of GSCs and
some GSCs remain inactive in standard conditions [32].
In addition, differentiated glioma cells have been
reported to reprogram towards a stem cell phenotype in
hypoxia and acidic conditions, suggesting that GSC can
be a dynamic stage because of cancer cell plasticity
[33,34]. Taken together, these studies implicate that
microenvironment conditions can regulate GSC activ-
ities and development. Recently, we found that the
human glioma cell line LN-229 failed to form neuro-
spheres in serum-free conditions, suggesting that GSCs
in LN-229 are not active in these conditions or they are
absent in this line. Therefore, in this study, we used the
LN-229 cell model to investigate the effects of IL-1b
and TGF-b on development of GSCs.
Materials and methods
Cell culture
Human glioma cell lines U87, T98, U138, and D54 were
obtained from the American Type Culture Collection
(Manassas, VA, USA). LN-229 was a kind gift from Dr.
Gilbert Cote (MD Anderson Cancer Center, Houston,
TX, USA). All cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (Invitrogen
Corp., Carlsbad, CA, USA) in a humidified incubator
with 37°C and 5% CO2. For neurosphere induction, cells
were cultured in serum-free medium (SFM), which con-
sisted of neurobasal-A medium supplemented with B27,
GlutaMAX-I supplement, 1% penicillin-streptomycin
(Invitrogen Corp.), 50 ng/ml heparin (Sigma-Aldrich, St.
Louis, MO, USA), 20 ng/ml of EGF, and 20 ng/ml bFGF
(R&D Systems, Minneapolis, MN, USA). To induce neu-
rosphere formation of LN-229 cells, 200 pM IL-1b and
200 pM TGF-b1 (both from R&D Systems) were added
every other day to the serum-free medium. IL-6 and IL-
8 (both from R&D Systems) were also used to evaluate
their effects on induction of neurospheres.
Self-renewal assay and cell proliferation assay
LN-229 cells at a clonal density of 1 cell/μli ns e r u m -
free medium were seeded at 100 μl/well in 96-well
plates and treated with or without 200 pM IL-1b and/or
200 pM TGF-b1 for seven days. IL-1b and TGF-b1 were
added every other day. The total number of neuro-
spheres in each well was counted under a microscope.
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tion kit I (MTT, Roche Applied Science, Indianapolis,
IN, USA) as described by the manufacturer.
RNA extraction and RT-PCR
Total RNA was extracted using TRI reagent (Sigma-
Aldrich), followed by digestion with a DNase kit
(Applied Biosystems, Carlsbad, CA, USA) to remove
DNA residues. Reverse transcription was carried out
using the iScript cDNA synthesis kit (Bio-Rad, Hercules,
CA, USA) and quantitative real-time PCR was per-
formed using SsoFast Eva Green Supermix kit (Bio-Rad).
Immunostaining and immunoblotting
LN-229 cells were seeded in slide chambers (Fisher
Scientific, Hanover Park, IL, USA) and cultured for
seven days in serum-free medium in the absence or pre-
sence of IL-1b/TGF-b. Then, cells were fixed with 4%
paraformaldehyde, permeablized with PBS containing
0.2% Triton X-100, and incubated with mouse anti-nes-
tin (1:50; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and followed by secondary chicken anti-mouse
IgG (H+L) antibody conjugated with Alexa 488 (1:200,
Invitrogen). Cells were then mounted with VECTA-
SHIELD Mounting Medium with DAPI (Vector labora-
tories, Burlingame, CA, USA) and observed with a
confocal microscope.
LN-229 cells were cultured in SFM in the absence or
presence of IL-1b/TGF-b for seven days. Cells were
then washed with cold PBS, lysed in RIPA buffer (25
mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS) and pelleted by centri-
fugation. Protein concentrations were determined using
a NanoDrop instrument (Thermo Scientific, Wilming-
ton, DE, USA). Cell lysates (30 μg protein for each sam-
ple) were incubated for five minutes at 100°C in 2x
loading buffer, separated by electrophoresis in 10% poly-
acrylamide gels, and transferred to PVDF membranes
(Millipore, Bedford, MA, USA). Membranes were
blocked with 5% milk in PBS and then incubated with
primary antibody anti-Bmi-1 clone F6 (1:1,000 dilution,
Millipore), or anti-b-actin (1:1,000 dilution, Sigma), and
secondary antibody HRP-conjugated goat anti-mouse
IgG-HRP (1:1,000 dilution, Millipore) or anti-rabbit IgG
HRP-linked antibody (1:1,000 dilution, Cell Signaling,
Danvers, MA, USA), respectively. Detection was per-
formed using HyGLO substrate (Denville Scientific,
Metuchen, NJ, USA) and images were taken using the
AlphaEaseFC imaging system (Cell Biosciences, Santa
Clara, CA, USA).
Invasion assay
The invasion assay was performed using 24-well Matri-
gel invasion chambers (BD Biosciences, San Jose, CA,
USA). Single control monolayer cells and IL-1b/TGF-b-
induced neurosphere cells were resuspended in serum-
free medium and loaded into the top inserts (2.5 × 10
4/
500 μl). DMEM with 20% FBS was added to the lower
chamber (750 μl) as a chemoattractant. After incubation
for 48 h at 37°C, non-invasive cells were removed from
the top of the matrigel with a cotton tipped swab. Inva-
sive cells that migrated through 8-μmp o r e st ot h e
underside of the membrane were fixed with 100%
methanol and stained with 0.005% crystal violet before
counting under a microscope.
Chemoresistance assay
Control monolayer and IL-1b/TGF-b-induced neuro-
sphere cells in serum-free medium were treated with
temozolomide (Sigma-Aldrich) at a concentration of
250, 500, 1,000 μM for two days. Then cells were
stained with Trypan blue (Amresco Inc., Solon, OH,
USA) and counted under a microscope. The viability of
the cells was measured by the percentage of live cells
over the total of live and dead cells.
Soft-agar colony-forming assay
T h es o f ta g a ra s s a yw a sp e r f o r m e di ns i x - w e l lp l a t e s
containing two layers of Sea Plague Agar (Invitrogen).
The bottom layer consisted of 0.8% agar in 1 ml of
DMEM with 10% FBS. Control monolayer and IL-1b/
TGF-b-induced neurosphere cells were dissociated and
placed (1 × 10
4/well) in the top layer containing 0.4%
agar in the same medium as the bottom. Cells were cul-
tured for two to three weeks and colonies were photo-
graphed under a microscope and measured using the
ImageJ program (http://imagej.nih.gov). Colonies with
diameters larger than 80 μm were counted.
Transfection of LN-229 cells with Gaussia luciferase
LN-229 cells were transfected with a pCMV-Gluc-1 vec-
tor encoding the Gaussia luciferase gene (Nanolight
Technology, Pinetop, AZ, USA) using Lipofectamine
2000 (Invitrogen). The stable transfectants were selected
with gentamicin-418 at 1,000 μg/ml. Expression of Gluc
w a sc o n f i r m e db yal u c i f e r a s ea s s a yw i t ht h eI V I S
Lumina II imaging system (Caliper Life Sciences, Hop-
kinton, MA, USA).
Implantation of LN-229 cells into immunocompromised
mice
The LN-229 cells stably expressing Gluc were used for an
in vivo study. Athymic nude mice (nu/nu, six to seven
weeks old; Charles River Laboratories, Wilmington, MA,
USA) were stereotactically implanted with the control
monolayer cells (3 × 10
5 cells/mouse) or IL-1b/TGF-b-
induced neurosphere cells (3 × 10
5 cells/mouse) in 3 μlo f
PBS into the right striatum (1 mm anterior and 2 mm
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after implantation, animals were subjected to biolumines-
cence imaging, followed by euthanization. Brains were
removed, placed in Tissue-Tek O.C.T. compound (Sakura
Finetek, Torrance, CA, USA), and quickly frozen in liquid
nitrogen. The frozen tissues were then stored at -80°C
until sectioning as described below. All animal procedures
were approved by the Institutional Animal Care and Use
Committee (IACUC) of Kansas S t a t eU n i v e r s i t ya n dt h e
IACUC number is 2813.
Bioluminescence imaging
Bioluminescence imaging was performed using the IVIS
Lumina II imaging system (Caliper Life Sciences). To
determine the correlation between the number of Gluc-
expressing cells and the bioluminescence signal in vitro,
various numbers of the monolayer or IL-1b/TGF-b-
induced neurosphere cells were used, and images were
taken one minute after a substrate for Gluc (60 μg/ml
coelenterazine) was added to the serum-free medium.
For in vivo bioluminescence imaging, coelenterazine
(150 μg/animal in 150 μl of PBS) was given i.v.; animals
were anesthetized with 2.5 to 3% isoflurane for approxi-
mately two minutes and then placed inside the camera
box (Caliper Life Sciences) that maintained 2% isoflur-
ane for the duration of imaging. The imaging scan time
for each animal was one minute.
Coelenterazine synthesis and solution preparation
Coelenterazine was synthesized by an extensive modifica-
tion of the procedure reported by Adamczyk et al. [35].
Aminopyrazine was used as a starting material to generate
3,5-diboromoaminopyrizine as a building block for intro-
ducing the pyrazine moiety of coelenterazine. A series of
Negishi coupling reactions was used to cross-couple the
benzyl and 4-hydroxyphenyl groups to 3,5-diboromoami-
nopyrizine by using Huo’sa n dB u c h w a l d ’sa p p r o a c ht o
zincation [36,37]. The complete synthesis and characteri-
zation of coelentearzine will be published separately.
Coelenterazine and hydroxypropyl-beta-cyclodextrin
(Acros Organics, Pittsburgh, PA, USA) (1:50, w:w) was
dissolved in methanol (ACS grade). Methanol was
removed by high vacuum distillation to obtain a dry yel-
low powder of the mixture of coelenterazine and cyclo-
dextrin. This mixture was dissolved in autoclaved
distilled water prior to imaging. A total of 150 μLo f
coelentrazine (1 mg/mL coelenterazine), which is the
substrate for Gaussia luciferase, was injected i.v. prior to
tumor imaging.
Brain sectioning, H&E staining and tumor volume
calculation
M o u s eb r a i n sw e r ec r y o s t a t - c u ta t1 0μmt h i c k n e s si n
coronal sections, mounted on Probe One Plus slides
(Fisher Scientific) and stained with an H&E stain kit
(BBC Biochemical, Stanwood, WA, USA).
Enzyme-linked immunosorbent assay (ELISA)
Cells were treated with or without IL-1b and TGF-b in
serum-free medium for six days. Cells were then washed
with PBS and cultured in serum-free medium without
cytokines for 24 h at 37°C. Cell supernatants were har-
vested and assayed for IL-1b and IL-8 using Quantikine
ELISA Kits (R&D Systems) as described by the
manufacturer.
Statistical analysis
Student’s t-test was used to determine statistical signifi-
cance for all analyzed data except the in vivo biolumi-
nescence signal experiment. A Fisher’se x a c tt e s tw a s
used to compare the percentage of mice with positive
bioluminescence signals. In all cases, we consider a two-
sided P < 0.05 significant.
Results
The combination of IL-1b and TGF-b induced neurosphere
formation of LN-229 cells in serum-free medium
In a preliminary study of GSCs, we compared the
growth properties of human glioblastoma cell lines U87,
T98, U138, D54 and LN-229 in serum-free medium
supplemented with EGF and bFGF. A single cell line,
LN-229, did not grow as neurospheres, but monolayer
cells under these conditions (Figure 1A). Immunocyto-
chemical analysis showed that the monolayer culture of
LN-229 cells had low level expression of nestin (a well-
known neural stem/progenitor cell marker) (Figure 2C).
The lack of neurosphere formation and low nestin
expression of LN-229 culture in serum-free medium
suggests that GSCs are absent in the LN-229 cell line or
they are inactive in this condition.
IL-1b and TGF-b are highly expressed in malignant
gliomas and associated with poor prognosis of glioma
patients. Therefore, we hypothesized that TGF-b and
IL-1b may contribute to GSC growth. To test the
hypothesis, we investigated whether IL-1b and TGF-b
could induce neurosphere formation of LN-229 cells.
IL-1b, TGF-b, or the combination of both cytokines was
added to LN-229 cell culture in serum-free medium. As
shown in Figure 1A, very few clusters were formed in
the presence of IL-1b or TGF-b alone and most cells
remained as a monolayer in the seven-day cultures.
However, in the presence of IL-1b and TGF-b,L N - 2 2 9
cells proliferated as clusters at first, which then grew
b i g g e ra n dd e t a c h e df r o mt h eb o t t o mo fp l a t e st of o r m
neurospheres. The neurosphere formation induced by
IL-1b/TGF-b, but not IL-1b or TGF-b alone, indicates a
synergistic effect of IL-1b and TGF-b on the induction
of neurospheres.
Wang et al. Stem Cell Research & Therapy 2012, 3:5
http://stemcellres.com/content/3/1/5
Page 4 of 16To avoid cell aggregation that leads to neurosphere
formation, LN-229 cells were plated in 96-well plates at
a clonal density of 1 cell/μl in serum-free medium in
the presence or absence of IL-1b and TGF-b.A ss h o w n
in Figure 1B, 8% of the LN-229 cells treated with IL-1b/
TGF-b formed neurospheres. Meanwhile, we compared
the proliferation rates of LN-229 monolayer cells and
IL-1b/TGF-b-induced neurospheres using an MTT
assay. As shown in Figure 1C, neurospheres induced by
IL-1b/TGF-b grew significantly (P < 0.05) more slowly
than the untreated monolayer cells.
IL-1b/TGF-b-induced neurosphere cells express stem cell
markers
To further characterize IL-1b/TGF-b-induced neuro-
spheres and determine the molecular mechanisms
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Figure 1 The combination of IL-1b and TGF-b induces neurosphere formation of LN-229 cells. (A) Representative images of LN-229 cells
in the absence or presence of IL-b and TGF-b. LN-229 cells (10,000 cells/well) were cultured in six-well plates containing serum-free medium
(SFM) in the absence or presence of 200 pM IL-1b or/and 200 pM TGF-b for seven days. Scale bar = 200 μm. (B-C) Neurosphere formation and
proliferation of LN-229 cells cultured at a clonal density (1 cell/μl) in 96-well plates containing 100 μl SFM in each well with or without IL-1b/
TGF-b for 14 days. (B) The percentage of newly formed neurospheres per well in the presence IL-1b/TGF-b.* P < 0.05. (C) IL-1b/TGF-b-induced
neurosphere cells proliferated more slowly than control cells, as demonstrated using an MTT assay. Error bars represent SEM. *P < 0.05.
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sion of several stemness genes in LN-229 cells treated
with or without IL-1b,T G F - b, or the combination of
both in serum-free medium. Using real time PCR, we
found that the expression of nestin, Notch2. Bmi-1 and
LIF was up-regulated significantly in IL-1b/TGF-b-
i n d u c e dL N - 2 2 9n e u r o s p h e r e s ,w h i l et h e yw e r es l i g h t l y
increased in cells treated with IL-1b or TGF-b alone,
Figure 2 IL-1b/TGF-b-induced neurosphere cells express stem cell markers. (A) Transcription levels of stemness genes in control and IL-1b/
TGF-b-induced neurospheres. LN-229 cells were cultured in SFM with or without IL-1b/TGF-b for seven days. Differential mRNA levels of stem
cell markers were determined by qRT-PCR. b-actin was used as an internal normalization control. Error bars represent SEM. *P < 0.01. (B)
Immunoblot analysis for Bmi-1 on cell lysates from control monolayer cells and IL-1b/TGF-b-induced neurospheres. b-actin was used as an
internal normalization control. (C) IL-1b/TGF-b-induced neurospheres express nestin, as demonstrated using an immunostaining assay. LN-229
cells were cultured in SFM with or without IL-1b/TGF-b for seven days and stained with anti-nestin antibody. Nuclei (blue stain) were
counterstained with DAPI. Scale bar = 20 μm.
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expression of Bmi-1 and nestin in IL-1b/TGF-b-induced
neurospheres was further confirmed by immunoblotting
and immunofluoresence staining, respectively (Figure
2B, C). These results indicate that the pathways of IL-1b
and TGF-b signaling interact to augment the expression
of stemness genes, leading to the formation of neuro-
spheres (Figure 1A).
IL-1b/TGF-b-induced neurospheres of LN-229 cells
displayed augmented drug resistance and cell migration
To determine whether IL-1b/TGF-b-induced neuro-
spheres possessed typical GSC properties, such as drug
resistance and invasiveness, we first compared the cyto-
toxic effect of temozolomide, a chemotherapeutic agent
for human glioblastomas, on control monolayer LN-229
cells and IL-1b/TGF-b-induced neurospheres. Control
LN-229 and neurosphere cells were treated with various
concentrations of temozolomide for two days. Cell viabi-
lity was measured as the percentage of live cells relative
to total cell number (dead + live cells). As shown in Fig-
ure 3A, IL-1b/TGF-b-induced neurospheres displayed
significantly (P < 0.01) greater resistance to temozolo-
mide at concentrations range from 250 to 1,000 μM.
We then evaluated the invasiveness of IL-1b/TGF-b-
induced neurospheres using a transwell migration assay.
Equal numbers of dissociated single cells from IL-1b/
TGF-b-induced neurospheres and control monolayer
LN-229 cultures were placed on transwell inserts. Inva-
siveness was measured by counting the cells that had
migrated through the insert 48 h post inoculation (Fig-
ure 3B). It was found that twice as many of IL-1b/TGF-
b-induced neurosphere cells migrated through the insert
compared to that of control cells (Figure 3C).
To understand the molecular mechanisms underlying
the enhanced migration, we examined the gene expres-
sion profile of several proteins that are known to be
involved in cell migration and invasion. It was found
that the expression of Smad interacting protein 1 [SIP1;
also known as zinc finger binding protein 2 (ZEB2)], b-
integrin and neuronal (N)-cadherin were significantly (P
< 0.005) increased in IL-1b/TGF-b-induced neurosphere
cells compared to that in control LN-229 cells (Figure
3D). This result suggests that SIP1, b-integrin, and N-
cadherin might be involved in the migration of IL-1b/
TGF-b-induced neurosphere cells.
IL-1b/TGF-b-induced neurospheres displayed increased
oncogenic potential in vitro and in vivo
To assess the oncogenic potential of IL-1b/TGF-b-
induced neurospheres, we performed a colony-forming
assay that is frequently utilized for in vitro evaluation of
malignant transformation and tumorigenesis [31]. Cyto-
kine-induced neurospheres and control monolayer LN-
229 cells were disassociated and then seeded in soft agar
at the same concentration. The total number and size of
colonies formed in soft agar wells were determined after
the cells were cultured for 14 days. As shown in Figure
4, IL-1b/TGF-b-induced neurosphere cells generated
significantly more (Figure 4 B )a sw e l la sl a r g e r( F i g u r e
4C) colonies than the control monolayer cells, indicating
that IL-1b/TGF-b-induced neurosphere cells possessed
higher oncogenic potential.
To further evaluate the oncogenic potential of IL-1b/
TGF-b-induced neurosphere cells, we examined whether
the cytokine-induced neurosphere cells can form tumors
in vivo. Bioluminescent imaging, which has been
recently established to monitor and quantify in vivo
tumor growth and cell survival [38,39], was used in our
study to track brain tumor development from injected
LN-229 cells transfected with a vector expressing Gaus-
sia luciferase (Gluc). LN-229 cells stably expressing Gluc
were established and cultured in serum-free medium in
the absence or presence of IL-1b/TGF-b for seven days.
The relationship between bioluminescent signal strength
and cell number was determined using various numbers
of cells from either control monolayer cells or IL-1b/
TGF-b-induced neurospheres. It was found that biolu-
minescent signals generatedf r o mb o t hp o p u l a t i o n sh a d
a strong positive linear correlation with cell number
within the range tested (Figure 5A). However, control
monolayer LN-229 cells displayed a higher level of Gluc
activity than cytokine-induced neurospheres. This find-
ing is consistent with the report that luciferase expres-
sion is higher in monolayer tumor cells than in tumor
neurospheres [40].
In the present study, mice were injected with control
monolayer cells or IL-1b/TGF-b-induced neurosphere
cells (3 × 10
5/mouse) intracranially. Five weeks after
implantation, tumor growth was evaluated using an IVIS
imaging system that measures luciferase expression level
within the brain. A positive signal for tumor growth was
recognized when the signal detected at the injection site
was at least three-fold of that at a non-injection site
(that is, background) on each mouse. Based on this stan-
dard, it was found that one out of four mice bearing the
control monolayer cells and six out of six mice bearing
the IL-1b/TGF-b-induced neurosphere cells showed
positive signals for tumor growth (Figure 5B, C). This
result suggests that IL-1b/TGF-b-induced neurosphere
cells have significantly (P < 0.03) greater capability of
generating tumors that can be detected by a biolumines-
cence imaging system. This difference is more pro-
nounced if one considers that monolayer LN229 cells
expressed higher amount of Gluc than did the cytokine-
induced sphere cells (Figure 5A).
To verify the in vivo tumor growth, brains were col-
lected from animals on Day 35 post implantation and
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Figure 3 IL-1b/TGF-b-induced neurosphere cells show enhanced drug resistance and invasiveness.( A) IL-1b/TGF-b-induced neurosphere
cells develop drug resistance. The control and IL-1b/TGF-b-induced neurosphere cells were treated with various concentrations of temozolomide
for two days. Then, cells were dissociated and stained with Trypan blue, and counted under a microscope. The viability was determined by the
percentage of live cells over the sum of live and dead cells. *P < 0.01. (B, C, D) IL-1b/TGF-b-induced neurosphere cells have stronger
invasiveness and enhanced invasive gene expression. LN-229 cells were cultured in SFM in the absence or presence of IL-1b/TGF-b for seven
days and then the control monolayer cells and IL-1b/TGF-b-induced neurosphere cells were dissociated. 5 × 10
4 cells of each group were placed
on the top well of a Matrigel Invasion chamber. DMEM medium with 20% FBS was added to the lower chamber. After 48 h of incubation, non-
invaded cells were removed from the top chamber and invaded cells at the lower surface were fixed and stained with 0.005% crystal violet.
Representative images of migrated cells were shown in (B). Migrated cells/well were counted under a microscope and reported in (C).* P < 0.01.
(D) Transcription levels of invasive genes in control monolayer and IL-1b/TGF-b-induced neurosphere cells. LN-229 cells were cultured in SFM in
the absence or presence of IL-1b/TGF-b for seven days and relative gene expression was determined by qRT-PCR analysis. b-actin was used as
an internal normalization control. Error bars represent SEM. *P < 0.005.
Wang et al. Stem Cell Research & Therapy 2012, 3:5
http://stemcellres.com/content/3/1/5
Page 8 of 16processed for H&E staining as described in Materials
a n dm e t h o d s .F i g u r e5 Ds h o w st h er e p r e s e n t a t i v e
images of middle sections of tumors from mice bearing
IL-1b/TGF-b-induced neurosphere cells or control
monolayer LN-229 cells with negative bioluminescence
signals. Although tumors were detected by H&E staining
at the injection site in all mice, the failure to detect a
bioluminescence signal in tumors from mice implanted
with the control monolayer LN-229 cells suggests that
the sensitivity of this bioluminescence imaging system is
limited.
IL-1b/TGF-b-induced neurosphere cells maintained higher
levels of Bmi-1 gene expression and oncogenic potential
after cytokine removal
To determine whether IL-1b/TGF-b-induced neuro-
sphere cells still maintained self-renewal ability to form
neurospheres in the absence of these two cytokines,
neurospheres were dissociated into single cells and
cultured in serum-free medium without IL-1b and TGF-
b for seven days. The cytokine-withdrawn (CW) cells
grew mostly as monolayer cells with some clusters, a
mixed morphology of control (CTL, no IL-1b and TGF-
b) and continued cytokine-treated (CT) cells (Figure
6A). Expression of stemness genes, including nestin,
LIF, Bmi-1 and Notch-2 in these three types of LN-229
cells was analyzed using real time PCR. As shown in
Figure 6B, expression of nestin and LIF in cytokine-trea-
ted cells was augmented as reported earlier (Figure 2A),
but their expression in cytokine-withdrawn cells was
reduced to the same level as control cells. Although
Notch-2 expression was dramatically reduced in cyto-
kine-withdrawn cells compared to that in cytokine-trea-
ted cells, it was still significantly (P < 0.001) higher than
that in control LN-229 cells. However, the key finding
was that the expression of Bmi-1 in cytokine-withdrawn
cells remained as elevated as that in cytokine-treated
cells (Figure 6B).
Figure 4 IL-1b/TGF-b-treated cells form more and larger colonies than control cells in soft agar. Single control or IL-1b/TGF-b-treated cells
were plated in soft agar containing DMEM and 10% FBS in six-well plates at a density of 10,000 cells/well and cultured for 14 days. (A)
Representative images of the colonies derived from the control and IL-1b/TGF-b-induced neurosphere cells. Scale bar = 100 μm. Colony number
was counted under a microscope as shown in (B) and size was measured using ImageJ as shown in (C). Twenty random fields were selected for
measurement and the data represent the average colony number and size per microscope field. *P < 0.001.
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was evaluated by a colony forming assay. Control, cyto-
kine-treated and cytokine-withdrawn cells were disso-
ciated into single cells. Then, an equal number of cells
from each group were cultured in soft agar and colonies
were counted after 21 days. Consistent with previous
results, cytokine-treated cells generated significantly (P <
0.005) more and larger colonies than control LN-229
cells (Figure 6C). Interestingly, cytokine-withdrawn cells
produced a similar number of colonies as cytokine-trea-
ted cells but with a slightly reduced size. However, their
size was still significantly (P < 0.004) larger than that of
colonies generated by control cells (nearly two-fold, Fig-
ure 6C). This result indicates that the molecules
responsible for the augmented in vitro oncogenic poten-
tial remained active in cytokine-withdrawn cells.
IL-8 might be involved in IL-1b/TGF-b-mediated induction
of LN-229 neurospheres
To test whether other cytokines are involved in IL-1b/
TGF-b-mediated induction of LN-229 neurospheres,
we compared the gene expression of IL-6 and IL-8 in
IL-1b/TGF-b-induced neurospheres and control cells
using real time PCR. IL-1b gene expression was also
examined to determine whether there was an auto-
crine positive feedback for IL-1b expression. It was
found that mRNA levels of IL-6 and IL-8 were drama-
tically increased in the neurosphere cells induced by
Figure 5 IL-1b/TGF-b-induced neurosphere cells have increased tumorigenic potential.( A) Bioluminescence characteristics of LN-229 cells.
Various numbers of LN-229 cells expressing Gaussia luciferase were cultured in 96-well plates in SFM in the absence or presence of IL-1b/TGF-b
for seven days, then incubated with 60 μg/ml coelenterazine and imaged with a scan time of one minute. After imaging, cells were counted
under a microscope. The relationship between bioluminescent signal strength and cell number for control monolayer LN-229 cells (left panel)
and for IL-1b/TGF-b-induced neurosphere cells (right panel) was reported here. (B) Representative images of mice injected intracranially with
control or IL-1b/TGF-b-induced neurosphere cells. 3 × 10
5 cells of the control monolayer or IL-1b/TGF-b-induced neurosphere cells expressing
Gaussia luciferase were injected into each nu/nu mouse brain at 1 mm anterior, 2 mm from bregma to right lateral and 3.5 mm
intraparenchymal. Images were taken five weeks after cell injection, two minutes after administering coelenterazine i.v. with a scan time of one
minute. (C) The percentage of mice which had at least three times higher bioluminescent signal at the injection site than the background signal.
*P < 0.05. (D) H&E staining of cryosectioned mouse brain five weeks after injection with control monolayer cells or IL-1b/TGF-b-induced
neurosphere cells. Small black arrows demarcate tumor margin. (III) and (IV) Amplified images of the areas indicated by rectangles in (I) and (II),
respectively. Scale bars in (I) and (II) = 200 μm. Scale bars in (III) and (IV) = 100 μm.
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Page 10 of 16IL-1b/TGF-b, compared to that in control cells (Fig-
ure 7A). IL-1b gene expression was also up-regulated
in cytokine-induced neurospheres, indicating that IL-
1b can induce its own biosynthesis in LN-229 cells.
Augmented expression and secretion of IL-1b and IL-
8f r o mI L - 1 b/TGF-b-induced neurospheres were
further confirmed using cytokine-specific ELISA (Fig-
ure 7B).
To determine whether IL-6 and IL-8 are involved in
IL-1b/TGF-b-mediated induction of neurosphere forma-
tion, LN-229 cells were stimulated with IL-6 or IL-8
alone, or in combination with TGF-b in serum-free
medium for seven days. Interestingly, IL-6 alone or in
combination with TGF-b failed to induce neurosphere
formation (data not shown). In contrast, neurospheres
were induced in the presence of IL-8 and TGF-b,b u t
Figure 6 Cytokine-withdrawn cells after initial IL-1b/TGF-b exposure retain stem-like properties. (A) Representative images of LN-229 cells
cultured in SFM in the absence (CTL, (control)) or presence of IL-1b/TGF-b (CT, (IL-1b/TGF-b)), or after withdrawal of both cytokines following
initial exposure (CW, (IL-1b/TGF-b®CTL)) for seven days. Scale bar = 200 μm. (B) qRT-PCR analysis of gene expression of stem cell markers in
CTL, CT and CW cells. b-actin was used as an internal normalization control. (C) The number and size of colonies formed in soft agar. CTL, CT
and CW cells were dissociated and 10,000 cells/well of each population were cultured in soft agar in six-well plates for 21 days. Colony number
was counted under a microscope and colony size was measured using ImageJ. Twenty random fields were selected for the measurement and
the data represent the average colony number and size per microscope field. *P < 0.05. **P < 0.01. Error bars represent SEM.
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that IL-8 signaling might be involved in IL-1b/TGF-b-
mediated induction of LN-229 neurospheres. However,
similar to IL-1b and TGF-b, IL-8 signaling alone is not
sufficient for the induction of neurospheres from mono-
layer LN-229 cells.
Discussion
Cytokines secreted either by cancer cells themselves or
by the surrounding stromal cells and infiltrating leuko-
cytes are thought to play a critical role in glioma malig-
nancy [41]. IL-1b and TGF-b are elevated significantly
in high grade gliomas and that has been associated with
poor prognosis in glioma patients [42-45]. Despite
recent advances in neuro-oncology, the contribution of
IL-1b and TGF-b to glioma development and recurrence
has not been clearly delineated. Here, we demonstrate
that the combination of IL-1b and TGF-b can promote
self-renewal and oncogenic capability of glioma cells by
inducing expression of stemness factor genes Bmi-1, LIF
and Notch-2.
In this study, we found that a human tumorigenic
glioma cell line LN-229 grew as a monolayer culture
and expressed nestin at a very low level under serum-
free conditions. Addition of both IL-1b and TGF-b,b u t
not each cytokine alone, to the cell cultures caused
monolayer cells to form neurospheres expressing up-
regulated nestin together with other stemness genes
including LIF, Notch-2 and Bmi-1. The neurospheres
could be induced by IL-1b/TGF-b when LN-229 cells
were plated at a clonal density, and proliferated at a
much slower rate than the control monolayer cells. This
behavior is consistent with traits of cancer stem cells
that divide more slowly than cancer cells [46]. Com-
pared to control monolayer culture, IL-1b/TGF-b-
induced neurosphere cells formed more and larger colo-
nies in soft agar, and displayed increased chemo-resis-
tance, invasiveness and oncogenic potential, all of which
Figure 7 Role of IL-1b, IL-6 and IL-8 in IL-1b/TGF-b-induced LN-229 neurosphere formation.( A) Relative gene expressions of IL-1b,I L - 6 ,
and IL-8 were determined by qRT-PCR. b-actin was used as an internal normalization control. Error bars represent SEM. *P < 0.05. (B) Secretion
of IL-1b and IL-8 from control LN-229 cells and IL-1b/TGF-b-induced neurosphere cells. The same number of LN-229 cells was cultured in SFM
with or without IL-1b/TGF-b for six days, and then culture media was removed. Cells were washed with PBS, and cultured in fresh SFM without
IL-1b/TGF-b for 24 hours. The media were collected, followed by ELISA analysis. N/D: not detected. (C) Combination of IL-8 and TGF-b induce
formation of neurospheres. LN-229 cells were cultured in SFM in the presence or absence of IL-8 or IL-8/TGF-b for seven days. Scale bar = 200
μm.
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indicate that IL-1b/TGF-b-induced neurospheres con-
tain an enriched population of GSCs. This finding sup-
ports the hypothesis that IL-1b/TGF-b may promote
glioma progress and recurrence by inducing self-renewal
of glioma cells.
The IL-1b/TGF-b-induced LN-229 neurospheres dis-
played increased nestin expression (Figure 2), but were
CD133
- (data not shown). CD133 has often been used
as a GSC marker [33,47]. However, recent studies reveal
that GSCs can be either CD133
+ or CD133
-, but both
types of GSCs express nestin in serum-free conditions
and are capable of self-renewal and generate highly
malignant tumors [48]. In addition, nestin expression
correlates well with histological grade of glioma and
clinical outcome [49]. Thus, nestin seems to be a more
critical marker for identification of GSCs.
LIF is a neuropoietic cytokine that stimulates self-
renewal capacity, prevents differentiation of NSCs and
GSCs in vitro and in vivo [31,50], and mediates TGF-b-
induced GSC self-renewal [31]. Up-regulation of LIF
expression in IL-1b/TGF-b-induced neurosphere cells
(Figure 2) supports that cytokine-induced neurosphere
cells are developed through self-renewal. However, con-
tinued up-regulation of LIF expression may not be
required for the maintenance of stemness as its expres-
sion in passage 2 of the neurosphere cells in the absence
of IL-1b and TGF-b is similar to that in control LN-229
cells (Figure 6).
Notch signaling is required for GSC proliferation and
blockade of the Notch pathway can inhibit the growth
of tumor neurospheres and xenografts [51,52]. Among
the four Notch paralogs, Notch-2 is highly expressed in
glioblastomas and may have a predominant role in glio-
blastoma cell growth [52,53]. Our studies have shown
that Notch-2, but not Notch-1 or Notch-3 (data not
shown), is up-regulated in IL-1b/TGF-b-induced neuro-
sphere LN-229 cells. This observation is consistent with
the thought that Notch-2 may play a major role in
glioma malignancy. Bmi-1, a transcriptional repressor
belonging to the polycomb group protein family, is
essential for the proliferation and self-renewal of NSCs
and GSCs [54,55]. Overexpression of Bmi-1 can induce
astrocytes into NSC-like cells under serum-free condi-
tion [56]. Thus, the augmented expression of Bmi-1 in
IL-1b/TGF-b-induced neurosphere LN-229 cells favors
the hypothesis that Bmi-1 plays a critical role in indu-
cing monolayer LN-229 cells to display a GSC
phenotype.
The role of Bmi-1 in GSC self-renewal and oncogenic
potential is further highlighted in cytokine-withdrawn
LN-229 cells. In the absence of IL-1b/TGF-b,d i s s o -
ciated IL-1b/TGF-b-induced neurosphere cells prolifer-
ated as a mix of monolayer and cluster cells, suggesting
a reduced self-renewal capability. Furthermore, the cyto-
kine-withdrawn cells maintained strong oncogenic
potential with a similar colony number as the cytokine-
induced neurosphere cells in a soft agar assay, but with
a slightly reduced neurosphere size. Gene expression
analysis showed that transcripts of nestin and LIF in
cytokine-withdrawn cells were reduced to the control
level. Notch-2 expression was also dramatically
decreased compared to that in cytokine-induced neuro-
spheres, but it was still significantly higher than that in
control LN-229 cells. Remarkably, Bmi-1 levels did not
decrease after cytokine withdrawal. The reduced expres-
sion of LIF and Notch-2 and sustained Bmi-1 expression
in cytokine-withdrawn cells are consistent with the
observation that these cells display a mixed phenotype
of monolayer and cluster cells and maintain a relatively
strong oncogenic potential. Our data support the notion
that Bmi-1 is critical for maintenance of GSC self-
renewal. However, we cannot exclude the possibility
that other unidentified factors are also involved in the
sustained clonogenicity of cytokine-withdrawn cells.
Future studies are planned to investigate the molecular
mechanisms of persistent expression of Bmi-1 and
Notch-2 in IL-1b/TGF-b-induced neurosphere cells
upon cytokine withdrawal.
Our data suggest that there is a close association
between increased expression of SIP1, N-cadherin and
b1-integrin and stronger invasiveness of the cytokine-
induced neurospheres. It has been reported that b1-
integrin is over-expressed in several types of gliomas
and blocking b1-integrin inhibits the motility and inva-
sion of glioma cells [57,58]. Similarly, N-cadherin, a cal-
cium-binding membrane glycoprotein that mediates
cell-cell adhesion, is up-regulated in malignant gliomas
cells compared to normal brain tissue [59], and plays a
critical role in glioma cell migration [60-62]. Reduction
of SIP1, a member of the ZEB family of transcription
factors, has been linked to the impairment of colony for-
mation in soft agar, migration and invasion of tumori-
genic glioma cells [63]; while overexpression of SIP1 in
nontumorigenic glioma cells enhances their colony for-
mation in soft agar, migration and invasion.
In addition, IL-1b, IL-6 and IL-8 and their cognate
receptors are also elevated in malignant gliomas [64,65].
Our studies have shown that IL-1b can also induce the
production of IL-6 and IL-8 in LN-229 neurospheres.
This result is consistent with previous reports that IL-1b
can induce the expression and secretion of IL-6 and IL-
8 in human gliomas [41,65,66]. However, it seems that
only IL-8, but not IL-6, is involved in IL-1b/TGF-b-
induced neurosphere formation from monolayer LN-229
cells. That is, only the combination of IL-8 and TGF-b,
but not the combination of IL-6 and TGF-b, can induce
neurospheres from LN-229 cells cultured in serum-free
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whether IL-6 and IL-8 participate in the IL-1b/TGF-b-
induced self-renewal of LN-229 GSCs.
Conclusions
In summary, we have used a human LN-229 glioma cell
line to examine the effect of IL-1b/TGF-b signaling on
induction of self-renewal and oncogenic capability of
glioma cells. Recent studies have focused on a small
population of GSCs, which are capable of self-renewal,
initiation of neurosphere growth and generation of
malignant tumors, for development of therapeutic stra-
tegies [12]. However, current standard in vitro condi-
tions to define GSCs lack cytokines that are highly
present in the glioblastoma microenvironment. Our
findings indicate that glioma cells that fail to self-renew
to generate neurospheres in standard stem cell-enrich-
ment conditions can gain this ability after exposure to
IL-1b and TGF-b. Thus, targeting GSC-promoting
microenvironment cytokines or interference with Bmi-1
may be essential for a higher efficacy of glioma thera-
pies. Future studies aimed to determine the molecular
mechanisms of IL-1b/TGF-b-mediated induction of self-
renewal may lead to the invention of novel therapies
that target the process of GSC activation.
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